U.S. to fund groundwork for ibogaine PTSD studies
Health Secretary Robert F. Kennedy Jr. and Veterans Affairs Secretary Doug Collins announced up to $4.9 million to prepare what could be the first U.S. studies of ibogaine, a psychedelic drug, for PTSD. The money covers manufacturing, dosing and study design, not patient trials. Ibogaine is illegal in the U.S. and can cause hallucinations, nausea, tremors and potentially deadly irregular heart rhythms. Texas company Beond, which has treated more than 3,000 patients in Mexico, will provide data and treatment guidance.
The day's 5 biggest stories, verified, free by email
▶ Watch the 90-second briefing (story 4 of 5) 🔔 Get 6 AM & 5 PM alerts
Why it matters
The money pays for making the drug, setting doses and designing studies, not for treating patients yet. Ibogaine remains illegal in the U.S. and carries serious heart risks, which officials say is why the effort focuses on safety first.
Sources
- AP via KSAT: Trump administration will fund new research on ibogaine
- The National News Desk via Local 12: US offers up to $4.9 million
Also in this edition
Get the catch-up in your inbox
The same fact-checked briefing, sources included, at 6 AM and 5 PM Central. No spin, no spam — unsubscribe anytime.
We only use your email to send the briefing.
